Kiora Pharmaceuticals, Inc. vs Kyverna Therapeutics, Inc. — Valuation Comparison 2026
Access all valuation models for KPRX vs KYTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →KPRX scores higher with a 5.5/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Kiora Pharmaceuticals, Inc. (KPRX) and Kyverna Therapeutics, Inc. (KYTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
KPRX currently trades at $2.83 with a QOC of 5.5/10, while KYTX trades at $8.65 with a QOC of 4.2/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).